Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,201–1,300 of 2,039
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Muraoka, N., Jensen, M. B., Kartha, V. K., Carrico, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678829 · Cited by 3
HIV Treatment and Obesity: What’s New?
Freitas, P., & Ribeiro, S. (2024) · Infectious diseases · doi:10.5772/intechopen.112667 · Cited by 2
Osonoi, T., Oura, T., & Hirase, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15296 · Cited by 2
Opalska, L., Muciek, A., Mocarska, M., Orłowska, A., Strakowska, K., Maryńczak, A., Mencel, J., & Nitschke, N. (2024) · Quality in Sport · doi:10.12775/qs.2024.35.56425 · Cited by 4
“For tirzepatide, diabetic retinopathy events have not been extensively studied, but the SURPASS trials report a similar pattern, with retinal issues noted but not in significant frequency [2].”
InfluentialAranishi, T., Igarashi, A., Hara, K., Osumili, B., Cai, Z., Mizogaki, A., Sato, M., Takeuchi, M., Minghetti, A., Hunt, B., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01675-7 · Cited by 2
Game changer: Navigating between challenges and hopes in geropharmacology
Chen, Q., Hartman, R., Dankiv, L., Yan, E., Young, L. H., & Barsotti, R. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.007 · Cited by 2
Heimann, A. S., Singh, P., Ferro, E. S., Greenway, F. L., & Krongrad, A. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70056 · Cited by 4
“These drugs have emerged as highly effective therapies for obesity and metabolic disorders, demonstrating significant weight‐loss benefits through mechanisms involving appetite suppression, delayed gastric emptying, and improved glycaemic control [52].”
Association of tirzepatide with erectile dysfunction in people with type 2 diabetes
Cowart, K., Murphy, C., & Carris, N. W. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109116 · Cited by 4
Abu-Alsaud, M. A., Ellebedy, M., Hammad, N., Lamie, M. I., & El-Rawy, A. F. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_213_24 · Cited by 2
Kang, Z., Jin, Z., Wu, L., Sun, A., Dong, L., Li, J., Li, Q., & Tong, X. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s524000 · Cited by 3
Birda, C. L., & Sebastian, S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01854-9 · Cited by 2
Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment
Sawamura, T., Ohmori, A., Kometani, M., Karashima, S., & Yoneda, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5779-25 · Cited by 4
Molecular Mechanisms Against Successful Weight Loss and Promising Treatment Options in Obesity
Szekeres, Z., Szabados, E., & Pálfi, A. (2025) · Biomedicines · doi:10.3390/biomedicines13081989 · Cited by 4
“Tirzepatide represents a promising pharmacological alternative with a bariatric-level efficacy [106].”
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178088 · Cited by 2
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., Valderas, E. G., Arad, A. D., Sharma, P., Dunn, J. P., Şenyücel, Ç., & Lee, C. J. (2025) · Obesity · doi:10.1002/oby.70014 · Cited by 3
Xiao, Y., Yu, S. P., Zhang, Y., Chen, J., Yan-qun, L., Liu, X., Sun, C., & Deng, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70105 · Cited by 3
Luo, M., Huang, L., Wang, H., & Zhao, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593917 · Cited by 2
Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review
Afshari, S., Khosravi, M., Zamandi, M., Rezapour, A., Hadian, M., Souresrafil, A., Mazaheri, E., & Gallehzan, N. A. (2025) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_368_24 · Cited by 5
“[18] Obesity has a significant economic burden on the health system and society.”
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis
Gurumurthy, G., & Thachil, J. V. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2712-3534 · Cited by 5
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Tejeji, I., Zeier, T., SMITH, J. A., CHANG, N. T., & Chao, L. C. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0493 · Cited by 2
“In adults with type 2 diabetes, however, Frias et al. have shown that all doses of tirzepatide are more e ffi cacious than semaglutide 1 mg in its weight loss e ff ect [16].”
InfluentialCardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 3
Therapeutic options and prognostic risk factors in diabetic foot osteomyelitis: a narrative review
Liu, Z., Huang, M., Ding, M.-C., Ma, X.-P., & Jiang, N. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003917 · Cited by 4
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J. (2025) · Diabetes Care · doi:10.2337/dc25-1836 · Cited by 3
Effects of incretin drugs on glycemic control and body weight
Levitskaya, A. N., Demidova, T. Y., & Геннадьевна, Л. К. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-07 · Cited by 2
Fakhir, S. D., Arif, I. S., & Waheed, H. J. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e175259 · Cited by 3
“The SURPASS-2 study indicated that TZP more effectively reduced glycated hemoglobin and fasting serum glucose levels than semaglutide across all doses (5, 10, and 15 mg) (Frías et al. 2021).”
Zhu, D., Ma, J., Wang, W., Shi, B., Dong, X., Bian, F., Li, Q., Wang, Y., Jiang, C., Wang, X., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06593-2 · Cited by 8
Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors
Khalil, A., Velikyan, I., Xiong, M., Bossart, M., Wagner, M., & Eriksson, O. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.106033 · Cited by 3
“12 Another multi-incretin receptor agonist, SAR441255, was designed to simultaneously activate GLP-1R, GIPR, and GCGR. 13 This drug design approach allows for maximising the insulinotropic effect by activating both GLP-1R and GIPR while enhancing the metabolic balance, energy expenditure, and…”
Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Adam, S., Ibrahim, F. M., Dabou, E. A. R., Pitre, S., Aiman, R., & AbdelSamad, S. (2025) · Healthcare · doi:10.3390/healthcare13233102 · Cited by 4
“Randomized trials demonstrate dose-dependent weight loss (e.g., SURPASS-2 in type 2 diabetes; SURMOUNT-1/3 in obesity), with emerging evidence of greater weight reduction versus semaglutide in some populations [3,4,8].”
Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes
Matza, L. S., Cutts, K. N., Coyne, K. S., & Boye, K. S. (2025) · Patient Related Outcome Measures · doi:10.2147/prom.s536043 · Cited by 2
“23 The outcomes of these new treatments, including substantial weight loss, may have a positive emotional impact on patients.”
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
Obesity and GEP-NEN: what’s new?
Boschetti, M., Hasballa, I., Patelli, I., Piras, G., & Albertelli, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.006 · Cited by 3
Kazi, M. A. I., Singh, S., & Haq, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248882 · Cited by 3
Alwafi, H. H., Alharbi, S. S., Al-adwani, G. A., Alsanosi, S., Oyelade, T., Almalki, F., Thalib, H. I., Naser, A. Y., Alfahmi, M. Z., Alotaibi, B. J., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639704 · Cited by 10
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
The Future of Obesity Management: Bridging Pharmacologic Innovation and Public Health
Qian, F., & Wang, L. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s579769 · Cited by 2
Sun, Y., Xia, Y. Y., Ge, W., & Li, Q. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178523 · Cited by 3
Tom-Ayegunle, K., Tom-Ayegunle, O., Okoye, S., Chukwuemeka, U., Adeyina, T., Babarinde, A. O., & Eleam, U. (2026) · Cureus · doi:10.7759/cureus.100947 · Cited by 5
Yang, Y.-T., Hou, X.-Z., Zhang, X.-R., Zhang, Z., & Wang, S.-H. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108671 · Cited by 2
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
Glucagon-like peptide-1 receptor agonists: a review of the literature from a dental perspective
O'Driscoll, J. A., & McIntyre, G. T. (2026) · BDJ · doi:10.1038/s41415-025-9345-4 · Cited by 4
Corrêa, L. M. D. A., Mazur, G. R., Santiago, C. B. G., Dante, L. E., Marco, P. S., & Ferrés, P. B. S. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101003 · Cited by 2
Schmidt, P. H. S., de Souza, V. S. N., Machado, L. G., Rodrigues, J. V. A., da Cruz, J. V. R., de Souza, L. S. N., dos Santos, B. E., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70529 · Cited by 7
Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
Guo, M., Chen, S., Dong, H., Cai, M., Guo, M., & Cheng, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05113-2 · Cited by 2
Khalifa, O., & Arredouani, A. (2026) · Pharmaceuticals · doi:10.3390/ph19030408 · Cited by 8
“With a half-life of ~5 days, it delivers synergistic metabolic effects and has demonstrated unprecedented improvements in both glycemic con-trol and weight reduction [45–47].”
Ostrominski, J. W., Ortega-Montiel, J., Wexler, D. J., Everett, B. M., CROMER, S. J., Byrne, C. F., Glynn, R. J., Paik, J. M., & Patorno, E. (2026) · Diabetes Care · doi:10.2337/dc25-3063 · Cited by 2
Mercado, D. O., Fadda, M., Beltrame, B., Tosi, M., Bruno, A., Scala, C. D., Travaglia, G., Vitale, A., di Cola, R. S., Boschetti, S., et al. (2026) · Dietetics · doi:10.3390/dietetics5010017 · Cited by 2
Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis
Provenzani, A., Mancuso, B., Stitch, R., Tuzzolino, F., Giusti, M. A., & Mattina, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1735987 · Cited by 2
“In SURPASS-1, which evaluated tirzepatide as monotherapy compared with placebo in patients treated with diet and exercise, HbA1c decreased by nearly 2% and body weight was reduced by approximately 9 kg (Rosenstock et al., 2021).”
InfluentialMinoda, Y., Ikeda, S., Inukai, K., Kishitani, S., Takeuchi, T., Aikawa, H., Saito, K., Kittaka, H., Hayashi, Y., Sawano, H., et al. (2026) · International Journal of Emergency Medicine · doi:10.1186/s12245-026-01170-9 · Cited by 4
“Tirzepa-tide has been shown to induce greater weight loss than GLP-1 receptor agonists alone [3, 4].”
Ko, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
Bianchi, C., Prato, S. D., Rothberg, A. E., & Nauck, M. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70674 · Cited by 3
Cetiner, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s594898 · Cited by 7
Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes
Kemmotsu, R., Okita, T., Koike, N., Inui, R., Tabuchi, Y., & Yasuda, T. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag054 · Cited by 4
“Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, has recently been introduced worldwide for the treatment of type 2 diabetes mellitus and obesity; it has potent effects on glycemic management and weight reduction [3-6].”
Almemari, S., Almulla, N., Alsarraf, Y., Badri, G., & Khan, N. S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02273-3 · Cited by 4
“Randomized controlled trials have reported dose-dependent metabolic effects of incretin-based therapies under standardized conditions, including incremental reductions in weight and blood pressure at higher doses [22].”
Wu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113273 · Cited by 2
Renke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
Khachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Guo, X., Zhang, J., Li, Q., Ye, Z., & Yuan, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71025 · Cited by 8
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 4
Self-citationSilverii, G. A., Velardi, V., Marinelli, C., Lax, A., Monami, M., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71128 · Cited by 3
“It can be speculated that the greater reduction of hyperglycemia and/or the more pronounced weight loss in comparison with other drugs, including GLP1RA [24], contributes to an improvement in the prognosis of cardiovascular events, thus reducing cardiovascular and all-cause mortality.”
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Heftdal, L. D., Carlander, A. F., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01248-1 · Cited by 3
Self-citationTerapia farmacologica dell’obesità: attualità e prospettive future
Vinciguerra, F., & Frittitta, L. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01068-7 · Cited by 2
“1 mg (p <0,001 per tutti i confronti) [19].”
BackgroundHarnessing the Incretin System with Multi-Agonists
Whyte, M., Heald, A. H., & Field, B. C. T. (2022) · EMJ Innovation · doi:10.33590/emjinnov/10115628 · Cited by 2
The Case for Bariatric Surgery in Patients with Class 1 Obesity
Scott, A. W., Leslie, D. B., Ikramuddin, S., Dutta, N., Amateau, S. K., & Wise, E. S. (2023) · Current Surgery Reports · doi:10.1007/s40137-023-00355-y · Cited by 2
Spatiotemporal Dynamics of GLP-1 Receptor and GIP Receptor Trafficking and Signaling in β Cells
Ayala, J. E. (2023) · Endocrinology · doi:10.1210/endocr/bqad056 · Cited by 2
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Aberle, J., Forst, T. M., Heitmann, E., Görgens, S. W., & Seufert, J. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2078-9491 · Cited by 4
“7 Anteil der Patienten:innen mit erreichten kombinierten Endpunkten in SURPASS-2 [30], SURPASS-3 [31] und SURPASS-5 [29].”
BackgroundInfluentialGIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
“…zeigen, dass der neuartige Wirkstoff eine äußerst vorteilhafte Wirkung auf die Senkung des glykierten Hämoglobins (HbA 1c ) und des Körpergewichts zeigt und die Effekte von potenten GLP-1-RAs (Dulaglutid und Semaglutid) sowie von Basalinsulinpräpara-ten übertrifft [24, 25, 26, 27, 28, 29].”
BackgroundInfluentialIncretin Analogs for Weight Management in Adults Without Diabetes
Lobkovich, A. M., Kale-Pradhan, P. B., & Lipari, M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231190089 · Cited by 4
“20-23 It is administered once weekly as a sub-cutaneous injection with a half-life of approximately 5 days.”
BackgroundNew Drug: Tirzepatide for type 2 diabetes
(2023) · Australian Prescriber · doi:10.18773/austprescr.2023.028 · Cited by 2
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Frühbeck, G., & Kiortsis, D. N. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128279822231211101522 · Cited by 2
Next-Generation Therapies for Type 2 Diabetes Mellitus
Patra, D., Roy, S., Ramprasad, P., & Pal, D. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-99-6597-7_13 · Cited by 3
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6797 · Cited by 2
“In all three doses (5, 10, 15 mg), tirzepatide was superior to sema - glutide in terms of glucose-lowering and weight-reducing effects [23].”
Safety of native glucose-dependent insulinotropic polypeptide in humans
Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171214 · Cited by 3
Long-Circulating Vasoactive 1,18-Octadecanedioic Acid–Terlipressin Conjugate
Berger, O., Choi, W., Ko, C. H., Thompson, M. P., Avram, M. J., Scott, D. J., Hoare, B. L., Cridge, R. R., Wheatley, M., Bathgate, R. A. D., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00305 · Cited by 2
Clinical management of MASLD and MASH—An overview
Horn, P., & Newsome, P. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00019-4 · Cited by 2
GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide
Oh, T. J. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.76 · Cited by 2
Incretin-mediated control of cardiac energy metabolism
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0011 · Cited by 2
Barakat, S., Ramdeen, S., & Khaimova, R. (2024) · Hospital Pharmacy · doi:10.1177/00185787241266803 · Cited by 3
Options for patients with out-of-control blood pressure: after all avenues have been exhausted
Zeng, W., & Tomlinson, B. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2401875 · Cited by 2
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 3
The User’s Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Butalia, S., BAJAJ, H. S., Jain, R., Leung, K., Mansell, K. D., Reichert, S. M., Senior, P. A., & Shah, B. R. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.003 · Cited by 4
Loh, W. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000892 · Cited by 4
“The gastrointestinal side effects of tirzepatide with semaglutide were similarly high at approximately 20% [19,20].”
InfluentialAlghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
Appendicitis After Initiation of Tirzepatide
Chan, G., Ansar, M., & Klein, M. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s496739 · Cited by 3
McKone, D. B., Duprey, K. S., Hall, H. M., Leonhard, A., Schadler, A. D., & Naseman, K. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0035 · Cited by 2
Goldberg, M., Blevins, J. E., Wolden‐Hanson, T., Elfers, C., Chichura, K. S., Ashlaw, E. F., den Hartigh, L. J., Roth, C. L., & Doyle, R. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073032 · Cited by 2
“…peptide-1 receptor (GLP-1R) agoniost, semaglutide, has resulted in a prolonged loss in body weight that has ranged from ≈ 6.7% over 40 weeks [5], ≈ 14.9% over 68 weeks [6], and ≈ 10.2% over 208 weeks [7], further highlighting the need to optimize anti-obesity treatment options that result…”
InfluentialAwad, A. A., Abouelmagd, A. A., Mohammed, F., Elettreby, A. M., Marey, M. M., Aldemerdash, M. A., Soliman, S. M., Belal, M. M., & Abosheaishaa, H. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2480512 · Cited by 4
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics
Tasma, Z., Garelja, M. L., Jamaluddin, A., Alexander, T. I., & Rees, T. A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108846 · Cited by 4
Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure
Malik, M. H. B. A., Khan, N. N., Chowdhari, M. J., Rafiq, M. K., Ali, M., Sadia, L. N. U., Ramzan, H. S., Ahmed, M. M., & Khatoon, F. (2025) · Cureus · doi:10.7759/cureus.82118 · Cited by 6
“This is in line with previous literature [3,4,14,15].”
Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists
Yang, Y., & Lin, Q. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118215 · Cited by 2
Random Blood Glucose: Episode 2
Aung, N. L. (2025) · Clinical Diabetes · doi:10.2337/cd25-0044 · Cited by 1
Morey‐Vargas, O. L., Gossmann, M., Ketz, J. M., & Abdelmalak, B. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24118 · Cited by 4
Wang, S., Fan, D., Yao, Q., & Sun, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16580 · Cited by 3
Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
Connelly, J. W., Narayanan, R., Ezeonu, T., Kothari, P., Spina, N., Spiker, W. R., Lawrence, B. D., Brodke, D. S., Schroeder, G. D., & Karamian, B. A. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001888 · Cited by 2
Zhang, J., Xu, H., Dong, Y., Feng, J., & Li, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118024 · Cited by 2
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
“Tirzepatide (TZP) is a dual GLP-1R/GIPR agonists and has excellent effects on weight loss and glycemic control in individuals with T2DM or obesity compared with the monotherapy of GLP-1R or GIPR agonists [18,19].”
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.